Is OPKO Health (OPK) A Bargain After Its Q2 Earnings And 52 Week High?

Simply Wall St.07-30

OPKO Health (OPK) moved into focus after its Q2 2026 earnings report and guidance, which showed revenue of US$163.58 million and a sharply lower net loss compared with the prior year period. See our ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655841786?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-30 11:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655841786","market":"hk","top_or_hot":-1,"title":"Is OPKO Health (OPK) A Bargain After Its Q2 Earnings And 52 Week High?","media":"Simply Wall St.","content":"<div>\n<p>OPKO Health (OPK) moved into focus after its Q2 2026 earnings report and guidance, which showed revenue of US$163.58 million and a sharply lower net loss compared with the prior year period. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/is-opko-health-opk-a-bargain-after-its-q2-earnings-and-52-we\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is OPKO Health (OPK) A Bargain After Its Q2 Earnings And 52 Week High?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs OPKO Health (OPK) A Bargain After Its Q2 Earnings And 52 Week High?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-30 11:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/is-opko-health-opk-a-bargain-after-its-q2-earnings-and-52-we><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OPKO Health (OPK) moved into focus after its Q2 2026 earnings report and guidance, which showed revenue of US$163.58 million and a sharply lower net loss compared with the prior year period. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/is-opko-health-opk-a-bargain-after-its-q2-earnings-and-52-we\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPK","symbol_name":"Opko Health","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/is-opko-health-opk-a-bargain-after-its-q2-earnings-and-52-we","article_id":"2655841786","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/is-opko-health-opk-a-bargain-after-its-q2-earnings-and-52-we","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655841786","pubTimestamp":1785381937,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"OPKO Health (OPK) moved into focus after its Q2 2026 earnings report and guidance, which showed revenue of US$163.58 million and a sharply lower net loss compared with the prior year period.\nSee our latest analysis for OPKO Health.\nOPKO Health shares have been volatile around the earnings release, with the 1-day share price return falling 17.27% after hitting a new 52-week high. However, the 90-day share price return of 24.09% and 1-year total shareholder return of 6.64% suggest momentum has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"OPK":"Opko Health"},"translate_title":"OPKO Health (OPK) 在第二季度收益达到 52 周高点后是否便宜？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPK":1.5},"content_text":"OPKO Health (OPK) moved into focus after its Q2 2026 earnings report and guidance, which showed revenue of US$163.58 million and a sharply lower net loss compared with the prior year period. See our latest analysis for OPKO Health. OPKO Health shares have been volatile around the earnings release, with the 1-day share price return falling 17.27% after hitting a new 52-week high. However, the 90-day share price return of 24.09% and 1-year total shareholder return of 6.64% suggest momentum has been building from a low base despite a weaker 5-year total shareholder return. If this kind of turnaround story has your attention, it can be worth scanning for other healthcare stocks with AI exposure using our curated list of 41 healthcare AI stocks OPKO Health now appears to be operating more as a functioning healthcare platform than a distressed story, yet the stock just swung from a fresh 52-week high to a sharp pullback. Do those new fundamentals line up with today’s share price? AdvertisementMost Popular Narrative: 69% Undervalued OPKO Health closed at $1.37 compared with a widely followed fair value estimate of $4.38. That gap reflects a very specific growth and margin story.  The sale of BioReference's oncology and related clinical testing assets to Labcorp is expected to sharpen OPKO Health's focus on its core testing business, drive significant cost savings, and support the Diagnostics segment's transition to cash flow positive and profitability in 2025, providing margin expansion and stabilizing earnings.  Read the complete narrative. Curious what has to happen for OPKO Health to reach that higher fair value. The narrative leans heavily on gradual revenue gains, margin repair, and a richer earnings multiple. Result: Fair Value of $4.38 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, OPKO Health still carries clear risks, including ongoing net losses and heavy R&D spending, as well as competition that could limit uptake of its key products. Find out about the key risks to this OPKO Health narrative. Another View on OPKO Health’s Valuation The fair value narrative for OPKO Health points to a large gap between the $1.37 share price and a $4.38 estimate. Yet on a simple P/S basis the stock looks expensive, trading at 1.7x versus a fair ratio of 0.6x, the US Healthcare average of 1.5x, and a 1.4x peer average. That kind of premium can limit upside if growth or margins do not move as hoped, so which signal do you trust more right now? To see how this pricing gap plays out in practice and what the numbers imply in different scenarios, take a closer look at the valuation breakdown using our P/S workup, then compare it with your own expectations for OPKO Health, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:OPK P/S Ratio as at Jul 2026Next Steps OPKO Health’s mixed signals on valuation and fundamentals can split opinion, so it makes sense to check the data directly and consider acting early if needed. A practical place to start is by reviewing the 3 important warning signs. Looking for more investment ideas beyond OPKO Health? If OPKO Health has you thinking more broadly about opportunities, do not stop here. Use the screener to uncover other stocks that fit your style before the market moves.  Target potential turnaround opportunities by scanning 20 elite penny stocks with strong financials that combine smaller market caps with stronger financial profiles than many peers. Zero in on value by reviewing 48 high quality undervalued stocks that pair solid fundamentals with prices that sit below fair value estimates. Focus on resilience by checking 85 resilient stocks with low risk scores that score well on balance sheet strength and overall risk metrics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655841786","isCrawlerRequest":true}